Federal regulations haven’t been issued for cannabidiol (CBD) yet, but that’s not stopping Americans from utilizing the cannabis compound, according to a survey released by Gallup on Aug. 7, 2019.

In fact, 1 in 7 Americans, or 14%, report using some form of CBD, primarily for therapeutic purposes.

The poll, which involved phone interviews with more than 2,500 adults from June 19 to July 12, illustrates the wide appeal of CBD nationwide since the 2018 Farm Bill was approved in December 2018, federally legalizing hemp and derivatives such as CBD.

Though young adults and people living in the West are the most likely to use CBD (20 and 21%, respectively), people from all demographics and regions are evidently partaking. Almost 1 in 10 individuals 65 or older use CBD, for example. And 13% of people from the South reported using the non-intoxicating ingredient, compared with 11% in both the Midwest and East.

Gallup also asked respondents about what they use CBD for and found that vast majority take it for medical purposes: 40% said they use CBD for pain, 20% for anxiety, 11% for sleep, 8% for arthritis, 5% for headaches and 5% for stress.

(The percentages in the chart don’t add up to 100 due to some respondents using CBD for multiple conditions.)

Overall, therapeutic uses accounted for about 90% of all responses, with just 5% total reporting recreational CBD consumption.

The survey offers another example of the explosive growth of the CBD industry and the strong interest among Americans in finding alternatives to pharmaceuticals for the treatment of various conditions, particularly pain.

But while CBD products are turning up everywhere — in grocery stores, dispensaries, gas stations, online, pet shops, and more — the Food and Drug Administration (FDA) is still in the process of developing rules to allow for marketing in the food supply or as dietary supplements. And so while access isn’t a problem, the agency has stressed that selling CBD products in that way isn’t currently permitted, though FDA is prioritizing enforcement against CBD companies that make unsanctioned claims about the therapeutic benefits of the products.

Former FDA Commissioner Scott Gottlieb wrote an op-ed for The Washington Post in July 2019 calling for the speedy development of CBD regulations so the agency can “fulfill its public-health obligations and meet the political demand for these goods.”

This article has been republished from Marijuana Moment under a content syndication agreement. Read the original article here.

Featured Image: Cannabidiol (CBD) has quickly taken hold in the American marketplace. According to a survey released Aug. 7, 2019, by Gallup, 14% of Americans, or 1 in 7, say they use CBD. The majority use it to treat pain or other medical conditions. Only 5% said they use CBD recreationally.  (Photo via Shutterstock)

Source link